Experimental drug Ulefnersen offers hope for rare, early-onset Amyotrophic lateral sclerosis (ALS) in clinical trials.

The $6.8m five-year initiative will provide palliative care from diagnosis onwards. Read more at straitstimes.com. Read more ...

On June 2, supporters across the U.S. will recognize the legacy of legendary baseball player Lou Gehrig and his impact on ALS ...

Neuronata-R® holds Orphan Drug Designation from both the U.S. FDA (2018) and the EMA (2019). CorestemChemon completed a Phase ...

In-home care can be the most preferred option for patients with progressive diseases such as amyotrophic lateral sclerosis ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company, has announced that the USFDA has granted ‘Fast Track ...

Melissa Diaz-Viera and her husband Robert Lang were overjoyed to have a baby after years of trying to get pregnant and also ...

Scientists from St. Jude Children's Research Hospital and Washington University in St. Louis report mechanistic insights into ...

Despite its devastating impact, ALS remains significantly underfunded and under-recognized in Canada. ALS Awareness Month is ...

Scientists found that stabilizing stress granules suppresses the effects of ALS-causing mutations, correcting previous models that imply stress granules promote amyloid formation.